These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17878401)

  • 1. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice.
    Vicente CP; He L; Tollefsen DM
    Blood; 2007 Dec; 110(13):4261-7. PubMed ID: 17878401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice.
    Vicente CP; He L; Pavão MS; Tollefsen DM
    Blood; 2004 Dec; 104(13):3965-70. PubMed ID: 15315969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin cofactor II modulates the response to vascular injury.
    Tollefsen DM
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):454-60. PubMed ID: 17194895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular dermatan sulfate and heparin cofactor II.
    Tollefsen DM
    Prog Mol Biol Transl Sci; 2010; 93():351-72. PubMed ID: 20807652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.
    Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI
    J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin cofactor II inhibits arterial thrombosis after endothelial injury.
    He L; Vicente CP; Westrick RJ; Eitzman DT; Tollefsen DM
    J Clin Invest; 2002 Jan; 109(2):213-9. PubMed ID: 11805133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.
    He L; Giri TK; Vicente CP; Tollefsen DM
    Blood; 2008 Apr; 111(8):4118-25. PubMed ID: 18281504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
    Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells.
    McGuire EA; Tollefsen DM
    J Biol Chem; 1987 Jan; 262(1):169-75. PubMed ID: 3793724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin cofactor II as a novel vascular protective factor against atherosclerosis.
    Aihara K; Azuma H; Akaike M; Sata M; Matsumoto T
    J Atheroscler Thromb; 2009 Oct; 16(5):523-31. PubMed ID: 19729870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin inhibition.
    Hayakawa Y; Hirashima Y; Kurimoto M; Hayashi N; Hamada H; Kuwayama N; Endo S
    FEBS Lett; 2002 Jul; 522(1-3):147-50. PubMed ID: 12095635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of heparin cofactor II by dermatan sulfate.
    Tollefsen DM; Pestka CA; Monafo WJ
    J Biol Chem; 1983 Jun; 258(11):6713-6. PubMed ID: 6687888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
    Sheehan JP; Tollefsen DM; Sadler JE
    J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan.
    Tanaka KA; Szlam F; Vinten-Johansen J; Cardin AD; Levy JH
    Thromb Haemost; 2005 Oct; 94(4):808-13. PubMed ID: 16270635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji).
    Kondo S; Tokunaga F; Kario K; Matsuo T; Koide T
    Blood; 1996 Feb; 87(3):1006-12. PubMed ID: 8562924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
    Buchanan MR; Brister SJ
    Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction of glycosaminoglycans with heparin cofactor II: structure and activity of a high-affinity dermatan sulfate hexasaccharide.
    Tollefsen DM
    Adv Exp Med Biol; 1992; 313():167-76. PubMed ID: 1442260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II.
    Shirk RA; Church FC; Wagner WD
    Arterioscler Thromb Vasc Biol; 1996 Sep; 16(9):1138-46. PubMed ID: 8792767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
    Derechin VM; Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II.
    Verhamme IM; Bock PE; Jackson CM
    J Biol Chem; 2004 Mar; 279(11):9785-95. PubMed ID: 14701814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.